세계의 재택 화학요법 서비스 시장

Global Chemotherapy At-Home Services Market to Reach US$2.8 Billion by 2030

The global market for Chemotherapy At-Home Services estimated at US$1.8 Billion in the year 2024, is expected to reach US$2.8 Billion by 2030, growing at a CAGR of 7.7% over the analysis period 2024-2030. Oral Chemotherapy, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the Infusion Chemotherapy segment is estimated at 5.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$464.8 Million While China is Forecast to Grow at 7.4% CAGR

The Chemotherapy At-Home Services market in the U.S. is estimated at US$464.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$439.2 Million by the year 2030 trailing a CAGR of 7.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.2% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.0% CAGR.

Global Chemotherapy At-Home Services Market - Key Trends & Drivers Summarized

Is the Future of Oncology Care Moving Beyond Hospital Walls?

The rising demand for patient-centric, accessible, and flexible cancer care is redefining traditional chemotherapy administration models, bringing chemotherapy at-home services into the spotlight. As healthcare systems globally seek ways to optimize oncology workflows and reduce patient exposure to hospital environments, at-home chemotherapy has emerged as a compelling alternative, particularly for low-risk patients and those undergoing maintenance treatments. The trend is gaining momentum, driven by advancements in portable infusion technologies, home-based monitoring tools, and evolving oncology care protocols that increasingly support decentralized service delivery. Hospitals and cancer centers are partnering with specialized home care providers to create hybrid care models, enabling oncologists to maintain oversight while patients receive infusions in the comfort of their homes. At-home services are proving especially beneficial in rural areas or for immunocompromised patients where travel poses significant burdens. Moreover, as health systems struggle with inpatient capacity constraints and growing oncology caseloads, shifting non-critical chemotherapy regimens to the home setting is reducing strain on infusion centers without compromising clinical outcomes. The COVID-19 pandemic accelerated the validation of this model, proving its safety, feasibility, and patient satisfaction levels across numerous pilot programs and public healthcare systems.

How Is Technology Enhancing Safety, Monitoring, and Delivery of Chemotherapy at Home?

Technological advancements have played a pivotal role in supporting the scalability and safety of at-home chemotherapy services. Portable infusion pumps, dose-controlled delivery systems, wearable patient monitoring devices, and smart infusion kits are now integral to enabling high-precision care outside clinical facilities. Digital tools such as remote patient monitoring (RPM), teleoncology platforms, and integrated electronic health records (EHR) allow care teams to track patient vitals, symptoms, and adherence in real time. This remote connectivity not only mitigates clinical risk but also enables timely intervention in case of complications, ensuring continuity of care. Pharmacovigilance tools and real-time analytics further support clinical decision-making by flagging early signs of adverse drug reactions or non-compliance. Mobile nursing units and oncology-trained homecare professionals are increasingly equipped with digital tools for safe drug administration and on-site patient support. The integration of cloud-based documentation platforms ensures secure communication between oncologists, pharmacists, and home healthcare teams, reducing clinical fragmentation. Additionally, advances in cold chain logistics and pre-filled infusion kits allow high-risk cytotoxic drugs to be safely stored, transported, and administered in non-clinical environments. These innovations collectively bridge the gap between institutional and home-based chemotherapy, making decentralized cancer care a viable and growing reality.

Why Are Patients and Payers Alike Embracing the Shift to Home-Based Oncology Services?

A key driving force behind the growth of chemotherapy at-home services is changing consumer behavior and payer dynamics. Patients today are increasingly prioritizing comfort, convenience, and autonomy in their treatment journeys. The psychological stress of hospital visits, risk of nosocomial infections, travel fatigue, and prolonged waiting times are major deterrents to conventional chemotherapy administration. At-home options offer a sense of control, emotional comfort, and normalcy, which are essential for improving treatment adherence and patient well-being. In parallel, health insurance providers and government-funded healthcare systems are recognizing the cost-effectiveness of home-based infusion services. Reducing hospital admissions, bed occupancy, and associated operational overheads significantly lowers the per-patient treatment cost without compromising quality of care. Consequently, reimbursement models are evolving to accommodate and incentivize home-based oncology services, especially for chronic regimens and palliative care patients. Additionally, patient satisfaction scores and quality-of-life metrics are becoming key performance indicators for healthcare delivery systems, further encouraging care model diversification. As the demographic of cancer patients becomes increasingly elderly and comorbid, mobility and accessibility concerns are also making home-based treatments more appealing to patients, caregivers, and providers alike.

What Is Driving the Rapid Growth in the Chemotherapy At-Home Services Market?

The growth in the chemotherapy at-home services market is driven by several factors rooted in technological progression, patient-centric healthcare models, evolving treatment protocols, and systemic healthcare restructuring. The increasing adoption of ambulatory infusion devices, digital health platforms, and remote monitoring technologies has created a strong technological foundation to support decentralized oncology care. Simultaneously, changing cancer treatment paradigms, with a shift toward more manageable, maintenance-based regimens, are making home-based chemotherapy a clinically viable option. Growing cancer prevalence, especially among aging populations, is expanding the demand pool for accessible, non-institutionalized treatment solutions. A broader emphasis on improving patient quality of life and reducing hospital dependency is influencing both clinical practice and healthcare policy. Payer support through insurance reimbursement and value-based care initiatives is accelerating the market uptake of at-home services. The emergence of specialized home infusion service providers and mobile oncology nursing teams is further fueling operational scalability. Moreover, public health system reforms and resource optimization strategies are institutionalizing hybrid care models that prioritize decentralized service delivery. Collectively, these factors are creating a fertile ecosystem for the growth of chemotherapy at-home services, redefining how cancer care is delivered in the modern era.

SCOPE OF STUDY:

The report analyzes the Chemotherapy At-Home Services market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Oral Chemotherapy, Infusion Chemotherapy); Cancer Type (Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer, Prostate Cancer, Ovarian Cancer)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 32 Featured) -

• Advocate Health at Home
• Amedisys
• Bayada Home Health Care
• BrightStar Care
• Bupa Cromwell Hospital
• Cancer Treatment Centers of America
• ChemoAtHome
• Clatterbridge Cancer Centre NHS Foundation Trust
• Coram CVS Specialty Infusion Services
• Healthcare at Home
• Home Instead
• Interim HealthCare
• Kindred at Home
• LHC Group
• LloydsPharmacy Clinical Homecare
• Option Care Health
• Penn Medicine Cancer Care at Home
• Sciensus
• UnityPoint at Home
• VITAS Healthcare

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Chemotherapy At-Home Services - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Preference for Patient-Centric Cancer Care Throws the Spotlight on At-Home Chemotherapy Services
  • Shift Toward Decentralized Healthcare Delivery Models Expands Addressable Market for Home-Based Oncology Services
  • Integration of Remote Monitoring Technologies and Teleoncology Drives Adoption of At-Home Infusion Solutions
  • Increasing Hospital Capacity Pressures and Staff Shortages Propel Growth in Alternate Site Cancer Care
  • Advancements in Portable Infusion Devices Strengthen the Business Case for Home-Based Chemotherapy Administration
  • Surge in Demand for Immunocompromised Patient Safety Accelerates Migration from Hospital to Home Settings
  • Growing Acceptance of Hybrid Care Models Generates Opportunities for Integrated Oncology Service Providers
  • Insurance Reimbursement Reforms and Value-Based Care Models Drive Wider Adoption of Chemotherapy At-Home Services
  • High Patient Satisfaction and Improved Quality of Life Metrics Sustain Growth Momentum in Home Infusion Programs
  • Expansion of Specialized Oncology Homecare Nursing Networks Spurs Market Scalability
  • Clinical Validation and Pilot Program Success Stories Strengthen Stakeholder Confidence in Home-Based Cancer Care Models
  • Rising Prevalence of Cancer in Aging Populations Creates Long-Term Demand for Accessible, Non-Hospital Treatments
  • Increasing Demand for Cost-Effective Treatment Pathways Drives Adoption in Public and Private Healthcare Systems
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Chemotherapy At-Home Services Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Chemotherapy At-Home Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Chemotherapy At-Home Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Oral Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Oral Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Oral Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Infusion Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Infusion Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Infusion Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Ovarian Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Ovarian Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Ovarian Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Colon Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Colon Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Colon Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Rectum Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Rectum Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Rectum Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Cervix Uteri Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Cervix Uteri Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Cervix Uteri Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Chemotherapy At-Home Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 35: USA Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Chemotherapy At-Home Services by Product Type - Percentage Breakdown of Value Sales for Oral Chemotherapy and Infusion Chemotherapy for the Years 2015, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Chemotherapy At-Home Services by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for Chemotherapy At-Home Services by Product Type - Percentage Breakdown of Value Sales for Oral Chemotherapy and Infusion Chemotherapy for the Years 2015, 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Chemotherapy At-Home Services by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer for the Years 2015, 2025 & 2030
• JAPAN
  • Chemotherapy At-Home Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: Japan 15-Year Perspective for Chemotherapy At-Home Services by Product Type - Percentage Breakdown of Value Sales for Oral Chemotherapy and Infusion Chemotherapy for the Years 2015, 2025 & 2030
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: Japan 15-Year Perspective for Chemotherapy At-Home Services by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer for the Years 2015, 2025 & 2030
• CHINA
  • Chemotherapy At-Home Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 53: China Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: China Historic Review for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: China 15-Year Perspective for Chemotherapy At-Home Services by Product Type - Percentage Breakdown of Value Sales for Oral Chemotherapy and Infusion Chemotherapy for the Years 2015, 2025 & 2030
  • TABLE 56: China Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: China Historic Review for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: China 15-Year Perspective for Chemotherapy At-Home Services by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer for the Years 2015, 2025 & 2030
• EUROPE
  • Chemotherapy At-Home Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 59: Europe Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 60: Europe Historic Review for Chemotherapy At-Home Services by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: Europe 15-Year Perspective for Chemotherapy At-Home Services by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 62: Europe Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Europe Historic Review for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: Europe 15-Year Perspective for Chemotherapy At-Home Services by Product Type - Percentage Breakdown of Value Sales for Oral Chemotherapy and Infusion Chemotherapy for the Years 2015, 2025 & 2030
  • TABLE 65: Europe Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Europe Historic Review for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: Europe 15-Year Perspective for Chemotherapy At-Home Services by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer for the Years 2015, 2025 & 2030
• FRANCE
  • Chemotherapy At-Home Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 68: France Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: France Historic Review for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: France 15-Year Perspective for Chemotherapy At-Home Services by Product Type - Percentage Breakdown of Value Sales for Oral Chemotherapy and Infusion Chemotherapy for the Years 2015, 2025 & 2030
  • TABLE 71: France Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: France Historic Review for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: France 15-Year Perspective for Chemotherapy At-Home Services by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer for the Years 2015, 2025 & 2030
• GERMANY
  • Chemotherapy At-Home Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 74: Germany Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Germany Historic Review for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Germany 15-Year Perspective for Chemotherapy At-Home Services by Product Type - Percentage Breakdown of Value Sales for Oral Chemotherapy and Infusion Chemotherapy for the Years 2015, 2025 & 2030
  • TABLE 77: Germany Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Germany Historic Review for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Germany 15-Year Perspective for Chemotherapy At-Home Services by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 80: Italy Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Italy Historic Review for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: Italy 15-Year Perspective for Chemotherapy At-Home Services by Product Type - Percentage Breakdown of Value Sales for Oral Chemotherapy and Infusion Chemotherapy for the Years 2015, 2025 & 2030
  • TABLE 83: Italy Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Italy Historic Review for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: Italy 15-Year Perspective for Chemotherapy At-Home Services by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Chemotherapy At-Home Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 86: UK Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: UK Historic Review for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: UK 15-Year Perspective for Chemotherapy At-Home Services by Product Type - Percentage Breakdown of Value Sales for Oral Chemotherapy and Infusion Chemotherapy for the Years 2015, 2025 & 2030
  • TABLE 89: UK Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: UK Historic Review for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: UK 15-Year Perspective for Chemotherapy At-Home Services by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Rest of Europe Historic Review for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Rest of Europe 15-Year Perspective for Chemotherapy At-Home Services by Product Type - Percentage Breakdown of Value Sales for Oral Chemotherapy and Infusion Chemotherapy for the Years 2015, 2025 & 2030
  • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Rest of Europe Historic Review for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Rest of Europe 15-Year Perspective for Chemotherapy At-Home Services by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Chemotherapy At-Home Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Asia-Pacific Historic Review for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Asia-Pacific 15-Year Perspective for Chemotherapy At-Home Services by Product Type - Percentage Breakdown of Value Sales for Oral Chemotherapy and Infusion Chemotherapy for the Years 2015, 2025 & 2030
  • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Asia-Pacific Historic Review for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Asia-Pacific 15-Year Perspective for Chemotherapy At-Home Services by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer for the Years 2015, 2025 & 2030
• REST OF WORLD
  • TABLE 104: Rest of World Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Rest of World Historic Review for Chemotherapy At-Home Services by Product Type - Oral Chemotherapy and Infusion Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: Rest of World 15-Year Perspective for Chemotherapy At-Home Services by Product Type - Percentage Breakdown of Value Sales for Oral Chemotherapy and Infusion Chemotherapy for the Years 2015, 2025 & 2030
  • TABLE 107: Rest of World Recent Past, Current & Future Analysis for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Rest of World Historic Review for Chemotherapy At-Home Services by Cancer Type - Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: Rest of World 15-Year Perspective for Chemotherapy At-Home Services by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Leukemia, Breast Cancer, Colon Cancer, Rectum Cancer, Cervix Uteri Cancer, Lung Cancer and Prostate Cancer for the Years 2015, 2025 & 2030

IV. COMPETITION